Managers / Q4 2023 · view latest →
Gates Foundation
CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100
Summary
Gates Foundation reported $90M in U.S.-listed holdings across 8 positions for Q4 2023.
The portfolio is heavily concentrated: IMCR alone accounts for 43.9% of reported value.
Compared with Q3 2023, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ADR · 72.7% · $65M
- Common Stock · 18.8% · $17M
- Other · 8.6% · $8M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AMYRIS INC | SOLD OUT | −292.4K | 0 | −$17,544 | $0 |
| IMCRIMMUNCORE HLDGS PLC | HELD | +0 | 576.9K | +$9M | $39M |
| CUREVAC N V | HELD | +0 | 1.63M | −$4M | $7M |
| EXSCIENTIA | HELD | +0 | 1.59M | +$3M | $10M |
| LUMIRADX LTD | HELD | +0 | 14.29M | −$3M | $857,143 |
| VIRVIR BIOTECHNOLOGY INC | HELD | +0 | 1.56M | +$1M | $16M |
| BNTXBIONTECH SE | HELD | +0 | 148.7K | −$460,889 | $16M |
| ATRECA INC | HELD | +0 | 912.6K | −$118,644 | $118,643 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | IMCRIMMUNCORE HLDGS PLChistory → | ADS | 43.85% | $39M | 576.9K |
| 2 | BNTXBIONTECH SEhistory → | SPONSORED ADS | 17.46% | $16M | 148.7K |
| 3 | VIRVIR BIOTECHNOLOGY INChistory → | COM | 17.45% | $16M | 1.56M |
| 4 | EXSCIENTIA | ADS | 11.35% | $10M | 1.59M |
| 5 | CUREVAC N V | COM | 7.60% | $7M | 1.63M |
| 6 | BFLYBUTTERFLY NETWORK INChistory → | CL A COM | 1.21% | $1M | 1.01M |
| 7 | LUMIRADX LTD | SHS | 0.95% | $857,143 | 14.29M |
| 8 | ATRECA INC | CL A COM | 0.13% | $118,643 | 912.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $44M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $60M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $84M | 8 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $90M | 8 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $84M | 9 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $126M | 9 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $113M | 9 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $130M | 9 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 10 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $130M | 9 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $186M | 11 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $330M | 11 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $342M | 10 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $692M | 8 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $656M | 7 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $438M | 5 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.